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ORIGINAL ARTICLE
Maternal Angiotensin Increases Placental Leptin 
in Early Gestation via an Alternative Renin-
Angiotensin System Pathway
Suggesting a Link to Preeclampsia
Olivia Nonn , Cornelius Fischer , Sabrina Geisberger , Amin El-Heliebi, Thomas Kroneis , Désirée Forstner,  
Gernot Desoye, Anne Cathrine Staff , Meryam Sugulle, Ralf Dechend , Ulrich Pecks , Martina Kollmann,  
Christina Stern, Judith E. Cartwright, Guy S. Whitley, Basky Thilaganathan , Christian Wadsack, Berthold Huppertz ,  
Florian Herse , Martin Gauster
ABSTRACT: Various studies found an association of different renin-angiotensin system (RAS) components with gestational duration 
and preterm birth, as well as with preeclampsia. Approximately 25% of first-time pregnant women develop a mild to severe 
hypertension in pregnancy or even preeclampsia. Based on recently published single-cell RNA-sequencing, we hypothesized 
an alternative RAS function in placenta and furthermore, an implication in hypertensive disorders in pregnancy. Placental RAS 
expression and localization was analyzed via quantitative polymerase chain reaction and in situ mRNA padlock probes. Tissue 
was collected from first-trimester elective termination (n=198), from healthy third-trimester controls (n=54), from early-onset 
preeclamptic (n=54) and age-matched controls (n=29), as well as first-trimester placentae from women with a high uterine 
artery resistance index (high-risk for preeclampsia, n=9) and controls (n=8). Serum levels of Ang (angiotensin) I to IV from 
women before and after conception were measured via mass spectrometry (n=10). Placental explants were cultured in 2.5% 
oxygen with Ang II, candesartan, and leptin. Seahorse XF96 MitoStress assays assessed trophoblast metabolism. Here, we 
show that maternal angiotensin acts on placental LNPEP (leucine aminopeptidase), that is, angiotensin IV-receptor and fetal 
angiotensin on placental AGTR1 (angiotensin II receptor type 1). Maternal circulating RAS shifts towards Ang IV in pregnancy. 
Ang IV decreases trophoblastic mitochondrial respiration and increases placental leptin via placental LNPEP. Lower placental 
LNPEP in preeclampsia and in first-trimester patients at high-risk for preeclampsia suggests a new alternative route in maternal 
RAS signaling and may contribute to hypertension and disease in pregnancy. The study shows how hypertensive disorders in 
pregnancy may be connected metabolic alterations that finally seem to contribute to the multifactorial disease in pregnancy, 
preeclampsia. (Hypertension. 2021;77:00–00. DOI: 10.1161/HYPERTENSIONAHA.120.16425.) • Data Supplement
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Blood pressure regulation in pregnancy is crucial to pregnancy outcomes. Approximately 25% of first-time pregnant women develop a mild to severe 
hypertension in pregnancy or even preeclampsia1 and 
37% develop elevated blood pressure but not overt 
hypertension.2 Women diagnosed with gestational 
hypertension experience increased morbidity, including 
augmented rates of caesarean deliveries, abruptio pla-
centae, and acute renal dysfunction.1 Depending on the 
country of origin, 10% to 50% of women initially diag-
nosed with gestational hypertension end up developing 
preeclampsia in as short a period as 1 to 5 weeks.3,4 
Conversely, chronic hypertension ranks second in risk 
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However, not only pregnancy and immediate mater-
nal and fetal morbidities are relevant to this topic, both 
mother and child suffer from an increased cardiovascular 
risk throughout their life following gestational hyperten-
sion and preeclampsia.6,7
Primary factors determining blood pressure are the 
sympathetic nervous system, plasma volume, vasopres-
sin, and the renin-angiotensin (Ang) system. While the 
physiological blood regulation in a nonpregnant state is 
fairly well understood, the pathophysiology of gestational 
hypertension is not fully elucidated. Antihypertensive 
treatment of nonsevere gestational hypertension does 
not reduce the incidence of complications such as pre-
eclampsia, placental abruption, preterm birth, or perinatal 
death.8 ARB (Ang receptor blocker) and ACE (ACE inhib-
itor) exposure during pregnancy have been associated 
with fetal oliguria, renal dysfunction, and death.9 Delivery 
is still the only effective treatment for preeclampsia.
Physiologically, Ang II regulates systemic blood pres-
sure via the AT1R (Ang II receptor type 1) and has thus 
been focus of extensive research regarding hypertensive 
disorders in pregnancy, such as preeclampsia.10–12 Vari-
ous studies found an association of different renin-Ang 
system (RAS) components with gestational duration 
and preterm birth (AGTR213), as well as with preeclamp-
sia.14–16 The crucial role of Ang II during pregnancy is 
suggested to be mainly mediated by AT1R (AGTR1), 
which is expressed in the placenta throughout gesta-
tion.17,18 Besides the classical RAS-pathway, including 
the substrate angiotensinogen (AGT), the enzymes renin 
(REN), and Ang-converting enzyme (ACE), the resulting 
peptides Ang I and II and their receptors type 1 (AGTR1) 
and type 2 (AGTR2), there is an extended RAS18,19 (see 
Figure S1 in the Data Supplement). Enzymes such as 
ACE2 convert Ang II to Ang (1–7) that acts on the Mas 
receptor. Aminopeptidase N (ANPEP), aminopeptidase 
A (ENPEP), dipeptidylpeptidase III (DPP3) convert prod-
ucts to the final Ang IV acting on AT4R (Ang IV recep-
tor), also called IRAP (insulin-regulated aminopeptidase), 
oxytocinase, vasopressinase, or placental leucinyl amino-
peptidase (LNPEP), which produces a soluble form only 
in human pregnancy.20
The novel technology single-cell RNA-sequencing 
(scRNA-seq) reveals a new insight into these complex 
Nonstandard Abbreviation and Acronyms
ACE angiotensin-conversion enzyme
AGTR1 angiotensin II receptor type 1
Ang angiotensin
ANPEP alanyl aminopeptidase
ARB angiotensin receptor blocker
ART assisted reproductive techniques
AT1R angiotensin II receptor type 1
GLUT4 glucose transporter type 4
hCG human chorionic gonadotropin
IRAP insulin-regulated aminopeptidase
LNPEP leucine aminopeptidase
MAS1  MAS1 proto-oncogene G-protein 
coupled receptor
OCR oxygen consumption rate
RAS renin angiotensin system
REN renin
scRNA-seq single-cell RNA-sequencing
SMA smooth muscle actin
Novelty and Significance
What Is New
• Renin-angiotensin system (RAS) receptor localization 
and missing angiotensinogen expression in placenta 
implicates a maternal and fetal circulating RAS.
• Maternal angiotensin acts on placental LNPEP (leu-
cine aminopeptidase), fetal angiotensin (Ang) on pla-
cental AGTR1 (Ang II receptor type 1)
• Ang III and Ang IV increase in pregnancy but not Ang 
I and Ang II.
• Ang IV acting on LNPEP decreases trophoblastic 
mitochondrial respiration and subsequently upregu-
lates placental leptin.
• Leptin downregulates placental LNPEP.
• Preeclamptic placentae and placentae from an early 
gestation high-risk population have decreased LNPEP 
compared with controls.
What Is Relevant
• RAS in pregnancy seems to have a shift towards an 
Ang IV/LNPEP/leptin pathway.
• The alternative RAS-pathway in pregnancy may explain 
some origins and effects of hypertensive disorders in 
pregnancy that are not yet elucidated.
• This Ang IV-accentuated RAS-pathway may play a role 
early in pregnancy when developing PE.
Summary
Maternal circulating RAS shifts towards Ang IV in 
pregnancy, decreases trophoblastic mitochondrial res-
piration, and increases placental leptin via placental 
LNPEP, that is, the Ang IV receptor. Lower placen-
tal LNPEP in PE and in early gestation higher-risk 
patients implicates a new alternative RAS mechanism 




 http://ahajournals.org by on A
pril 1, 2021
ORIGINAL ARTICLE
Hypertension. 2021;77:00–00. DOI: 10.1161/HYPERTENSIONAHA.120.16425 May 2021  3
Nonn et al Maternal Ang IV and Leptin in Preeclampsia
systems at the feto-maternal interface. Recent scRNA-
seq data published by Vento-Tormo et al21 led us to revisit 
the localization of placental RAS components, which 
revealed a unique picture of the placental RAS, showing 
a segregated localization of components in different cell 
types, differently than previously suggested.17,18 Based 
on this obtained novel picture of the placental RAS, we 
further on hypothesized an implication in hypertensive 
disorders in pregnancy.
METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request. For a 
detailed description of patient cohorts and sampling methods, 
cell culture methods, viability assay, RNA isolation, RT quanti-
tative polymerase chain reaction, gel electrophoresis, protein 
isolation, immunoblotting, immunofluorescence staining, FACS 
analysis, over-representation analysis,22,23 serum Ang measure-
ment in the Data Supplement.
Sample Collection
Samples from different patient biobanks were used to validate 
data: Placental tissue was collected from electively terminated 
gravidities of healthy patients in Graz, Austria (with gestational 
age 5–11 weeks; n=198). Healthy third-trimester samples 
were collected in the University Hospital of the RWTH Aachen, 
Germany (n=54). Serum samples were collected in a patient 
cohort undergoing assisted reproductive techniques (ART) at 
the Center for Gynecological Endocrinology and Reproductive 
Medicine, University Hospital Graz, Austria. Preeclamptic pla-
centae and respective controls were sampled at the University 
Hospital of Graz, Austria (n=42) and within an independent 
cohort15 at the Oslo University Hospital, Norway (n=33). 
Placental tissue from early gestation of patient populations at 
a lower and higher risk of developing preeclampsia (uterine 
artery resistance index >95 percentile: high risk for develop-
ing preeclampsia) and then undergoing elective terminations 
of pregnancy was sampled at St. George’s Hospital, London, 
United Kingdom (n=16).24,25 All participating women gave 
informed written consent, and all studies were approved by the 
local ethics committee. Villous samples were used and washed 
in PBS before processing and RNA or protein extraction. For a 
detailed description, please see the Data Supplement.
Serum Ang Measurement
The equilibrium levels of 4 different RAS Ang peptide metab-
olites (Ang I, Ang II, Ang III, Ang IV) in serum samples from 
ART patients were quantified by liquid chromatography-mass 
spectrometry/mass-spectroscopy performed at a service pro-
vider laboratory (Attoquant Diagnostics, Vienna, Austria) using 
previously validated and described methods.26 For a detailed 
description, please see the Data Supplement.
Placental Explants
First-trimester placental tissue was collected from women 
undergoing an elective termination of pregnancy before week 
12. Placental tissue was processed within 1 to 4 hours after 
the surgical intervention. Subsequently after washing in PBS 
(pH 7.0, 37 °C; Gibco, Life Technologies (TM), Thermo Fisher 
Scientific, Vienna, Austria), placental tissue was dissected 
under a stereoscopic microscope to obtain placental explants 
as described.27 After culturing placental explants, tissue was 
homogenized via UltraTurrax (IKA) in RNA Lysis Buffer (peqlab, 
VWR International, Avantor, Darmstadt, Germany), and RNA 
was isolated according to the protocol provided (peqlab, VWR 
International, Avantor, Darmstadt, Germany).
Placental explants (n=12) were cultured in DMEM/F12 
(1:1, Gibco) without supplements in a hypoxic workstation 
under physiological conditions with 2.5% oxygen for indicated 
time points at 37 °C for 3, 6, and 24 hours. Candesartan was 
used in its active form (Selleckchem, Munich, Germany) at a 
concentration of 0.1 µmol/L, Ang II was used at 0.1 µmol/L 
(Sigma-Aldrich, Merck, Vienna, Austria), Ang IV at a concen-
tration of 4 nmol (Sigma), Leptin at a concentration of 100 
ng/mL (Gibco).
In Situ mRNA Detection via Padlock Probes
In situ detection of mRNA with padlock probe technology 
was used to localize AGTR1 and CGB mRNA transcripts as 
described previously.28,29 In short, oligonucleotides and padlock 
probes were designed to capture all 5 mRNA transcript vari-
ants of AGTR1 and the one mRNA transcript of CGB. Padlock 
probe technology allows detection of mRNA transcripts directly 
within tissue samples, preserving its original location. An impor-
tant advantage of padlock probes are their high specificity in 
strong contrast to several AGTR1 (Ang II receptor type 1) anti-
bodies showing only low specificity.30 For further details and the 
oligonucleotide sequences, please visit the Data Supplement.
Quantitative Analysis of Padlocks In Situ
Slides were scanned with a TissueFAXS system in confocal 
mode and marker expression in virtual slides was quanti-
fied by StrataQuest Contextual Image Cytometry software 
(TissueGnostics GmbH, Austria). Briefly, the analysis pipe-
line was programmed to detect placental fetal vessels via 
fluorescence intensity in the according channel (CD34 
immunofluorescence staining). Background subtraction 
was obtained by an additional autofluorescence imaging. 
Padlocks were identified with a pipeline based on punctual 
fluorescence intensity. Distances of padlocks to fetal vessels 
were calculated automatically.
Seahorse XF Experiments
BeWo cells (ATCC clone, 4×105 per well) were seeded onto 
a Seahorse XFe96 microplate and incubated for 24 hours in 
DMEM/F12 medium (1:1, supplemented with glucose, pyru-
vate, 10% v/v FBS, 1% v/v penicillin+streptomycin; Gibco Life 
Technologies) at 37 °C before conducting the Seahorse XF 
Cell Mito Stress Test. Compounds were either added to culture 
medium provided with the Seahorse XF Cell Mito Stress Test 
Kit (Seahorse XF, Agilent Technologies, Santa Clara, CA) when 
an incubation time of max. One hour was chosen or to the cell 
culture medium when a preincubation protocol was chosen. For 
treatments, the according culture medium was supplemented 
with Ang II at a working concentration of 0.1 or 1 µmol/L, Ang 
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and oxygen consumption rate (OCR) were determined add-
ing D-Glucose to a final concentration as found in the culture 
medium (17.5 mmol/L), oligomycin to a final concentration of 1 
µmol/L, BAM15 to a final concentration of 1 µmol/L, and rote-
none and antimycin to a final concentration of 1 µmol/L each 
(compounds all from Sigma Aldrich, Germany). For normaliza-
tion, cells were detached after the Seahorse XFe Mito Stress 
test, and a nuclear staining with Hoechst was performed. Cell 
count was acquired with a BD FACSCanto II cell analyzer and 
analyzed with FlowJo v.10.
Single-Cell RNA-Sequencing Data
scRNA-sequencing data were aligned and quantified using 
the Cell Ranger Single-Cell Software Suite (version 3.0, 10x 
Genomics) 13 against the GRCh38 human reference genome. 
Cells with fewer than 300 detected genes and for which the 
total mitochondrial gene expression exceeded 20% were 
removed. Mitochondrial genes and genes that were expressed 
in fewer than 3 cells were also removed. Further bioinformati-
cal analysis was done using R package Seurat31 and RStudio; 
Uniform Manifold Approximation and Projection and t-distrib-
uted stochastic neighbor embedding projections were imported 
into Cell Loupe Viewer (version 3.0, 10x Genomics) for visual-
ization and cell annotation purposes.
Sc-RNAseq data published by Pique-Regi et al32 was used 
to evaluate effects of preterm labor, labor, and nonlabored term 
deliveries (Gene Expression Omnibus accession GSE114037, 
and ArrayExpress accession E-MTAB-6701), data from Vento-
Tormo et al21 was used to analyze RAS expression.
Statistical Analysis
Statistical analysis was performed with IBM SPSS Statistics 
25 and R 3.5.0. Graphs were created with GraphPad Prism 7. 
Some cases were excluded following outlier testing. Obtained 
data was first analyzed for normal distribution with the Shapiro-
Wilk test, and the statistically appropriate tests were then cho-
sen according to the results. Alpha was set at 0.05 and when 
needed adjusted for multiple testing and alpha-error-accumu-
lation with a Dunn or Holm-Sidak post hoc test. Homogeneity 
of variances was tested for by Levene test and, when appropri-
ate, Welch correction was used. A linear regression model was 
applied in the cohort data for the analysis of possible predictors.
RESULTS
Maternal and Fetal Angs Have Different Target 
Placental RAS Receptors
We analyzed expression levels of RAS components in 
annotated scRNA-seq data from first trimester placentae 
(Figure 1A; annotation Figure S2). AGT (gene encoding 
for the Ang II precursor angiotensinogen) was not detect-
able in placental tissue and must, therefore, be supplied 
by either the maternal or the fetal circulation. We further 
investigated the expression of Ang-converting enzymes 
REN, ACE, ACE2, ENPEP, ANPEP, RNPEP, DPP3 (Fig-
ure S1, modified from19), which were partially present in 
the placenta to convert exogenous Ang depending on 
cell type (Figure 1A). Out of 4 known Ang-receptors, only 
LNPEP and AGTR1 were expressed in placental tissue 
in both third-trimester and first-trimester placenta (Fig-
ure 1A; Figures S3 and S4). The cell cluster annotated as 
syncytiotrophoblast expressed LNPEP as the only Ang 
receptor, whereas AGTR1 was exclusively expressed in 
cells annotated as fibroblasts. Two other RAS receptors, 
MAS1 and AGTR2, were lacking placental expression. 
The same expression patterns were found in third-tri-
mester placentae (Figure S3).
Since both active receptors AGTR1 and LNPEP 
(leucine aminopeptidase) showed a different cell type 
expression, we hypothesized 2 independent RAS-path-
ways acting on the developing placenta, one of them 
fetal directed towards AGTR1 and the other maternal 
directed towards LNPEP as the target receptor. We, 
therefore, validated their localization in first-trimester 
placental tissue sections. CGB transcripts were local-
ized with padlock probe technology combined with an 
immunofluorescence staining for β-hCG (human chori-
onic gonadotropin β subunit), showing mRNA transcripts 
localized with the protein (Figure 1B, left). CGB encoding 
for β-hCG, a marker for syncytiotrophoblast (Figure 1B, 
red arrow), was expressed in the same cluster as LNPEP 
(Figure 1C, red arrow). An immunofluorescence staining 
against LNPEP shows its localization in the syncytiotro-
phoblast layer (Figure 1C, left).
scRNA-seq expression shows AGTR1 in cells express-
ing ACTA2, encoding for SMA (smooth muscle actin), a 
vascular smooth muscle cell marker (Figure 1D and 1E, 
blue arrows). Immunofluorescence staining with endothe-
lial marker CD31 reveals that cells around fetal vessels are 
stained for SMA (Figure 1D, right). AGTR1 transcripts were 
localized in first-trimester placental tissue sections using 
specific padlock probes for mRNA in situ hybridization 
(Figure S5) and were found to be localized, in line with the 
scRNA-seq data, around fetal vessels (Figure 1E, right).
Both localizations were concordant to scRNA-seq 
data, although we suggest the fibroblast population, 
annotated as fibroblasts, represents the myofibroblast 
population surrounding developing fetal-placental ves-
sels. To systematically evaluate the proximity of AGTR1 
transcripts to fetal vessels, AGTR1 padlock signals (Fig-
ure 1F) were quantitatively analyzed for their distance 
from the vessels with image analysis software (TissueG-
nostics StrataQuest; n=5; Figure S5) and compared 
with the distribution of ACTB transcripts in serial tis-
sue sections (n=3). Left-skewed distribution of AGTR1 
compared with a normal distribution of ACTB transcripts 
shows AGTR1 closer to fetal vessels (3.6 versus 66.0 µm 
median distance from fetal vessels).
Serum Ang IV Increases in Pregnancy
We then validated results via quantitative polymerase 
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Figure 1. Maternal Ang (angiotensin) and fetal Ang II have different target receptors.
First-trimester villous tissue was used, see schematic representation of a first-trimester chorionic villus cross section (center). A, Expression 
and localization of renin Ang system (RAS) components in single-cell RNA-sequencing data from first trimester: LNPEP is expressed in the 
syncytiotrophoblast (SCT), AGTR1 in fibroblasts (fFB2). AGT is not expressed in placenta. Dot circumference and intensity show expression 
level and percent expression. B, SCT marker β-hCG (human chorionic gonadotropin; CGB; right) expression in SCT cluster in scRNA-seq data 
(Uniform Manifold Approximation and Projection, red arrow) from first trimester placentae, localization of β-hCG (green) by immunofluorescence 
staining and CGB mRNA transcripts (red, arrow) by padlock probe technology (scale bar=50 µm; left). C, LNPEP expression in SCT cluster 
scRNA-seq data (right), localization of β-hCG (green) and LNPEP (red, arrow) by immunofluorescence staining (n=3, scale bar=50 µm; left). D, 
Vascular smooth muscle cell (VSMC) marker ACTA2 (smooth muscle actin [SMA]) expression in scRNA-seq data (left) and localization of SMA 
(blue) by immunofluorescence staining (CD31=red; right). E, AGTR1 expression in fFB2 cluster in scRNA-seq data (left). AGTR1 transcripts 
(blue, arrow) via padlock probe technology around fetal vessels (FV, red) in first-trimester placenta (combined with immunofluorescence staining; 
FV: CD34, red; SCT: β-HCG, green; scale bar=50 µm; n=10, gestational age weeks 7 and 11; right). F, AGTR1 transcripts (yellow) and actin 
beta transcripts (ACTB, pink) in first trimester placenta, combined with β-hCG (green) and CD34 (red) immunofluorescence staining (n=3, 
scale bar=50 µm). Histogram showing the transcript to vessel distance of AGTR1 transcripts (median is 3.6 µm from fetal vessels) and ACTB 
transcripts as control (median is 66.0 µm from fetal vessels). MA indicates maternal artery; MC, myocyte; MF, myofibroblast; MV, maternal vein; 
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expressed in placental tissue, while MAS1 and AGTR2 
were not detectable and AGT expression showed no 
placental expression, concordantly to the scRNA-seq 
data (n=8, Figure 2A; Figure S6). Expression levels 
across gestational age in healthy first trimester and 
third-trimester placentae (n=252; Table S5) were 
determined for placental RAS receptors AGTR1 and 
LNPEP, showing an overall increase across gesta-
tion (Figure 2B and 2C). This was validated by pro-
tein expression data showing a significant increase 
in LNPEP from first to third trimester (Figure 2D). 
Additionally, REN, DPP3, ENPEP, and ACE2 were also 
analyzed and displayed dynamic expression patterns 
across gestation (Figure S6). Furthermore, we ana-
lyzed fetal sex effects, maternal age, body mass index, 
and smoking habits with a linear regression model 
but did not see any effects on AGTR1 and LNPEP 
expression (Table S5). We next analyzed serum levels 
of maternal Ang I to IV (Figure 2E). Serum was col-
lected from women undergoing ART at 2 time points, 
nonpregnant before embryo-transfer and after con-
firmed pregnancy around week 7 (Table S6) to com-
pare intrapersonally the changes during pregnancy. 
The peptides Ang I (mean±SEM, 56.9±6.6 pmol/L) 
and Ang II (mean±SEM, 210.5±26.4 pmol/L) as 
measured by mass spectrometry showed no sig-
nificant increase in first trimester. On the contrary, 
serum Ang III (mean±SEM, 2.6±0.6 pmol/L) and 
Ang IV (mean±SEM, 4.6±1.0 pmol/L), the 2 peptide 
hormones resulting from Ang I and Ang II, were sig-
nificantly increased in pregnancy (Figure 2E). Interest-
ingly, Ang III is converted to Ang IV as a substrate 
of LNPEP, and Ang IV acts as an inhibitor of LNPEP 
activity.33,34
Maternal Ang II Has a Metabolic Role in 
Trophoblasts via LNPEP
Next, we were interested in the effect that Ang may 
have on the syncytiotrophoblast layer, that is in direct 
contact with maternal blood. As shown by scRNA-seq 
data, the syncytiotrophoblasts express LNPEP but not 
AGTR1. LNPEP is known as AT4R, but also as IRAP 
(insulin-regulated aminopeptidase) residing in vesicles 
with GLUT4 (glucose transporter type 4)35 and binding 
to acyl-coA-dehydrogenases at the cytosolic end.36 
We, therefore, investigated metabolic effects induced 
by Ang II and Ang IV in the trophoblastic cell line BeWo. 
We used Seahorse XF metabolic assays measur-
ing the extracellular acidification rate and OCR after 
1-hour Ang II treatment (Figures S7 and S8). Injection 
of glucose lead to an increase of extracellular acidi-
fication rate but, surprisingly, to a decrease in OCR. 
This pinpoints towards the highly glycolytic character 
of these cells. Basal OCR levels are decreased after 
Ang II treatment, but mitochondrial respiration after 
administration of the uncoupler BAM15 is unchanged 
(Figure 3A, Figure S8). BeWo cells showed a similar 
expression patterns of Ang receptors as found for 
syncytiotrophoblast by scRNA-seq (Figure 3B). Given 
that enzymes required to convert Ang II into Ang IV 
(ENPEP, DPP3, ANPEP, RNPEP) are expressed in 
BeWo cells, but no AGTR1 expression was found (Fig-
ure 3B), we suggested a shift from an Ang II to an 
Ang IV pathway. We, therefore, repeated the meta-
bolic assay with Ang IV treatment for 1 hour. Basal 
OCR remained decreased when treating cells with 
Ang IV (Figure 3C), again leaving maximal respira-
tion unchanged compared with controls (Figure S8). 
Overall, both Ang II and Ang IV reduced mitochondrial 
metabolism but had no effect on their maximal poten-
tial. Glycolytic capacity was decreased (Figure 3D). 
These effects of decreased mitochondrial metabolism 
are consistent between Ang II and Ang IV treatment of 
trophoblasts (Figure 3E and 3F).
Ang II Leads to an Increase of Leptin in a 
Placental Secretory Response
We next aimed to analyze the effect of Ang II on pla-
cental villous explants, a model most close to the situ-
ation found in vivo. We incubated villous explants with 
0.1 µmol/L Ang II for 6 hours under physiological oxy-
gen concentrations of 2.5% and analyzed transcriptional 
changes of genes involved in placental pathologies 
and genes associated with Ang pathways (Figure 4A). 
Analysis of the differentially expressed genes showed a 
significant upregulation of HMOX1, COL12A1, HPGD, 
ACTG2, LEP—downregulated genes were MMP9, IL1B, 
CD36, ANKRD55, CBX7, SLC24A2, VEGFC, VEGFA, 
PTPRD (Figure 4B). Among these genes, LEP encod-
ing leptin, had the highest fold change expression (3.98-
fold). Analyzing the differentially regulated genes in an 
over-representation analysis, GO terms such as ther-
mogenesis, female pregnancy, and nucleocytoplasmic 
transport were found to be significantly enriched (Table 
S4 and Figure S9). Further on, we validated array results 
in placental explants with the AT1R-blocker candesar-
tan over different time points (3, 6, and 24 hours; n=10; 
Figure 4C) and found that a significant upregulation of 
leptin mRNA expression after 6-hour 0.1 µmol/L Ang 
II treatment could not be inhibited by candesartan (Fig-
ure 4C, middle), suggesting mediation of Ang II effects 
by LNPEP and not AGTR1. This led us to the conclu-
sion that Ang II may mainly act on LNPEP in placental 
ex vivo tissue culture, resulting in an upregulation leptin. 
We, therefore, investigated whether leptin might regulate 
LNPEP expression as a feedback loop. We treated pla-
cental explants with a leptin concentration found physi-
ologically in pregnancy (100 ng/mL) and detected a 
decreased LNPEP mRNA expression (Figure 4D) and 
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LNPEP-Dependent Ang II Effects May Lead to 
LNPEP Downregulation in Preeclampsia
While some of LNPEP functions such as degrading 
oxytocin or vasopressin have been elucidated, it is still 
unclear why low soluble LNPEP serum levels are associ-
ated to pregnancy pathologies like gestational diabetes, 
fetal death, or hypertensive disorders in pregnancy.20,37
To determine whether only shedding or transcription 
is disturbed in preeclampsia, placentae from healthy 
and preeclamptic patients were analyzed for LNPEP 
expression. A significant downregulation of LNPEP 
gene expression was found in early and late-onset pre-
eclampsia (Figure 5A; Tables S7 and S8) compared with 
uncomplicated pregnancies. Furthermore, we investi-
gated possible early gestational effects and analyzed 
Figure 2. Maternal Ang (angiotensin) IV acting on placental renin (REN) Ang system (RAS) receptor LNPEP increases in 
pregnancy.
A, Quantitative polymerase chain reaction Validation of scRNA-seq data expression patterns of RAS components, 2 RAS receptors in placenta 
are AGTR1 (Ang II receptor type 1) and LNPEP, while no endogenous angiotensinogen (AGT) is expressed in human first-trimester placenta 
(n=8; mean and SEM; *not detected). B, AGTR1 and (C) LNPEP mRNA expression across gestation (n=252; nonlinear regression line; Table 
S5); (D) LNPEP protein expression (data are represented as mean with SEM; normality was tested by Shapiro-Wilk test followed by Mann-
Whitney test; *P≤0.05). E, Log-transformed values of Ang I–IV serum levels before and after conception in ART patients; Ang III and Ang IV 
show a significant increase in pregnancy (Ang I and Ang II=ns, normality was tested by Shapiro-Wilk test; paired t test with graph showing 
mean and SD for Ang I, II, IV, and Wilcoxon-signed-rank test with median and IQR for Ang III, sig. level 0.05; n=10; patient characteristics in 
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Figure 3. Maternal Ang (angiotensin) II and Ang IV have a metabolic role in trophoblasts.
A, Ang II (0.1 µmol/L) downregulates basal oxygen consumption rate (OCR) in BeWo trophoblast cells (mean and SEM, Seahorse XF 
data normalized to cell count; unpaired t test with Welch correction, P<0.05). B, scRNA-seq data of syncytiotrophoblast (SCT) and 
villous cytotrophoblasts (VCT). Expression analysis of renin Ang system (RAS) components by quantitative polymerase chain reaction 
shows LNPEP as only Ang receptor expressed in BeWo cells (term and first trimester placentae served as positive controls, n=3 for 
each; X=not detected; blue=low, red=high expression). C, Ang IV (4 nmol/L) downregulates basal OCR (mean and SEM; normalized, 
t test with Welch correction, P<0.05). D, Metabolic profile of Ang II and Ang IV treated cells relative to control (significant changes 
marked *P<0.05). E, Ang II and Ang IV alter metabolism similarly, significantly decreasing basal OCR levels (F) while maintaining a 
higher spare respiratory capacity (1 h pretreatment with 0.1 µmol/L Ang II or 4 nmol/L Ang IV; graph shows median and interquartile 
range, Mann-Whitney U test, Seahorse XF data normalized to cell count; P<0.05). AA indicates antimycin; ACE, Ang-converting enzyme; 
AGTR1, Ang II receptor type 1; DPP3, dipeptidyl peptidase 3; ECAR, extracellular acidification rate; ENPEP, glutamyl aminopeptidase; 
FT, first trimester; Glc, glucose; GRC, glycolytic reserve capacity; Omy, oligomycin; RNPEP, arginyl aminopeptidase; Rot, rotenone; and 
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Figure 4. Exogenous Ang (angiotensin) II leads to an increase of leptin, while leptin downregulates LNPEP in first trimester 
placental explants.
A, Heat map showing the gene expression in first-trimester placental explants incubated with 0.1 µmol/L Ang II for 6 h (at O2 2.5% 
physiological concentration; n=3). B, Volcano plot showing significantly regulated genes (P>0.05, regulation >1.5 fold). Significantly 
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first-trimester placenta samples from women classified 
by uterine artery Doppler ultrasound scanning as having 
a higher or lower risk of developing preeclampsia (uter-
ine artery resistance index >95 percentile: high risk for 
developing preeclampsia) and then undergoing elective 
terminations of pregnancy.24 LNPEP expression was sig-
nificantly decreased (Figure 5B; Table S9) in the placen-
tae derived from women with a high risk for preeclampsia.
Based on our data, we suggest that the downregula-
tion of LNPEP in high-risk pregnancies or preeclampsia 
may be the result of a first trimester leptin-driven negative 
feedback loop initiated by maternal Ang IV (Figure 5C).
DISCUSSION
While there is broad consensus that the human pla-
centa contains its own RAS from very early gestation 
onwards, our current study provides substantial experi-
mental evidence to challenge the existing doctrine of 
cellular distribution of placental RAS receptors. This 
current study identified LNPEP as the sole RAS recep-
tor at the maternal-placental interface, that is, the syn-
cytiotrophoblast. We localized AGTR1 exclusively at 
fetal-placental vessels, whereas neither AGTR2, nor 
MAS1 were detected in human placenta. Previous 
studies localized AT1R in a broad range of placental 
cells, including the syncytiotrophoblast, villous cyto-
trophoblasts, villous stroma cells, Hofbauer cells,17,38 
AT2R staining was identified in both villous and extravil-
lous trophoblast.39 When investigating the expression 
of MAS1 (MAS1 proto-oncogene G-protein coupled 
receptor), apelin, bradykinin, oxytocin, or vasopressin, 
we saw in the scRNA-seq data from Vento-Tormo et al, 
that none of these were expressed in villous placental 
tissue in the first trimester (Figure S4). Based on our 
findings, we propose a novel concept that gives insight 
into a shift to an alternative RAS pathway in human 
pregnancy. Accordingly, maternal Ang II acts on the pla-
centa by a shift towards its derivatives Ang III and Ang 
IV that are acting on the target receptor LNPEP, driving 
responses at the syncytiotrophoblast. The syncytiotro-
phoblast layer in direct contact with placental intervil-
lous maternal blood, and thus maternal Ang-derivatives, 
responds with a decrease in basal mitochondrial respi-
ration. Leptin increases and in a novel pathway, down-
regulates LNPEP—well in line with the results of lower 
expression of LNPEP we found in preeclamptic pla-
centae as well as in first trimester higher-risk patients. 
Previous studies also identified high maternal leptin in 
serum and placenta as a hallmark of preeclampsia.40,41
Leptin has long been investigated in cardiovascular 
research for its involvement in endothelial dysfunction, 
aneurysm, atherosclerosis—also in association with Ang 
and RAS components.42–44 Previous studies by Than et 
al45 show that leptin positively correlates with blood pres-
sure and that AGT plays a central role in functionally con-
necting differentially expressed features in preeclampsia. 
We are the first to show a direct relationship between 
maternal Ang and elevated placental leptin levels. This 
also allowed us to propose a pathophysiological mech-
anism around placental LNPEP. LNPEP is known as 
AT4R, oxytocinase, vassopressinase, placental LNPEP, 
but also as IRAP residing in vesicles with GLUT4 and 
binding to acyl-coA-dehydrogenases at the cytosolic 
end.35,36 The concept may explain the appearance and 
interdependence of hypertension, metabolic disorders 
in the form of maternal obesity or gestational diabetes, 
activation of cell-mediated immunity, and preeclampsia.
Maternal susceptibility genes in preeclampsia iden-
tified LNPEP in decidua46 together with AGT47 and in 
maternal blood with ANPEP.48 SNPs in LNPEP and 
associated sites were related to prematurity shown in 
maternal triads and to gestational length in general.49 
Maternal soluble form only in human pregnancy activ-
ity increases between the fourth and 38th weeks of 
gestation,50 leading to accelerated metabolism of its 
substrates such as vasopressin or oxytocin. However, 
its activity decreases in preterm delivery and severe 
preeclampsia.51 Its soluble fraction in maternal plasma 
is decreased with severe preeclampsia when compared 
with mild preeclamptic or normotensive pregnancies.52 In 
line with this observations, levels of serum copeptin—a 
by-product of vasopressin hydrolysis from its precursor—
were significantly elevated in women who subsequently 
developed preeclampsia, compared with controls across 
gestation.53,54 Hence, our data on decreased LNPEP 
in first trimester placental tissue from women with a 
higher risk of developing preeclampsia fits well in this 
concept and indicates that a disturbed LNPEP activ-
ity may also mirror its vasopressinase activity.51,52 In the 
overriding cohort24 of early pregnancies with a high risk 
for developing preeclampsia, there was no difference in 
the body mass index from high-risk and control groups. 
This heightens the suggested importance of the renin-
Ang system in preeclampsia. Altogether, LNPEP seems 
to have a fundamental role in sustaining a pregnancy.
Figure 4 Continued. MMP9, IL1B, CD36, ANKRD55, CBX7, SLC24A2, VEGFC, VEGFA, PTPRD (C) shows the relative LEP mRNA 
expression of placental explants incubated with Ang II (0.1 µmol/L) and AT1R (Ang II receptor type 1)-blocker candesartan (1 µmol/L) for 3 
h (left), 6 h (middle), and 24 h (right). LEP expression showed a 4.97-fold increase in first trimester placental explants after 6 h treatment, 
with no change at 3 or 24 h. No Ang II type 1 receptor blocker effect can be detected at 6 h. P<0.05; 3 h: n=4; 6 h: n=10; 24 h: n=8, graph 
shows median and range. D, LNPEP mRNA expression after 6 h Ang II, Ang IV, leptin treatment of first trimester placental explants: LNPEP is 
significantly downregulated after 6 h leptin treatment (fold change; mean and SD, n=3). E, LNPEP protein expression in first trimester placental 
explants treated with Ang II (0.1 µmol/L), Ang IV (4 nmol/L), and leptin (10 ng/mL) for 6 h, normalized to GAPDH (AUC fold change shown, 
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A strength of this study is that we confirmed reduced 
placental LNPEP expression in 2 independently 
recruited cohorts with preeclamptic patients. It is difficult 
to distinguish between preeclampsia effects and con-
founding factors related to preterm delivery and labor, 
unless gestational-age matched controls are available. 
Figure 5. LNPEP-dependent Ang (angiotensin) II effects may lead to LNPEP downregulation in preeclampsia (PE).
A, LNPEP mRNA is differentially expressed in early and late-onset PE (eoPE, loPE) when compared with controls (data z-transformed; 1-way ANOVA 
with multiple comparisons; P<0.05; see Tables S8 and S9 Graz and Oslo cohort). B, LNPEP expression is lower in first trimester placentae from 
women with a high uterine artery resistance index, indicating high-risk for PE (n=16; Mann-Whitney U test, P<0.05). C, Graphical summary of the 
proposed mechanistic pathway based on the results. Maternal and fetal Ang II and its conversion product Ang IV have different target receptors. 
Maternal Ang IV, that increases in pregnancy, acts on trophoblastic LNPEP and decreases basal oxygen consumption rate (OCR) in mitochondrial 
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As expected, our uncomplicated control pregnancy group 
has a significantly higher mean gestational age than the 
preeclamptic group (Graz cohort: 253.8±4.1 days (n=27) 
controls and 236.9±3.5 days (n=37) preeclamptic preg-
nancies; ∆=16.9 days), meaning that a reduced placental 
LNPEP expression could result from lower gestational 
age, differences between birth mode, general risk fac-
tors for preterm birth. We addressed these possible 
confounders by investigating available scRNA-seq data 
from Pique-Regi et al55 to evaluate effects of preterm 
labor, labor, and nonlabored term deliveries (Figure S10). 
We found no difference in LNPEP expression between 
these entities neither in villi, decidua nor chorioamniotic 
membranes. Hence, we conclude that LNPEP expres-
sion is likely not altered by labor stress, preterm birth, or 
risk factors that pertain to these pregnancy pathologies, 
but rather suggest it to be a preeclampsia-specific fea-
ture worth further investigation.
We could use smaller sample sizes for assessing a 
high-risk population and ART patients without the risk of 
overseeing confounders by using a large cross-sectional 
observational cohort of healthy first trimester placental 
samples to adjust for maternal and fetal characteristics. 
Using serum from women before undergoing ART and 
after a successful pregnancy in first trimester was the 
best method to intrapersonally adjust Ang levels in non-
pregnant and pregnant women’s serum by choosing a 
cohort that was documented to be nonpregnant and then 
pregnant and thus excluding variability between individu-
als as well as concentrating on changes in pregnancy.
In line with our findings, both LNPEP and ANPEP 
(Ang II induces placental AP-A) have previously been 
found to be expressed on the apical microvillous surface 
of the syncytiotrophoblast.56 On top, ANPEP hydrolyzing 
Ang II to Ang III in pregnancy.57 No longitudinal techni-
cally reliant data and composition of Angs in pregnancy 
was available up to date, and our data measured by mass 
spectrometry comparing prepregnancy and pregnancy 
levels of Angs in the same patients is unique. These new 
findings give an insight into entirely different, LNPEP-
centered baseline conditions regarding RAS in preg-
nancy. RAS components degrading Ang II to Ang III58 
were significantly increased in preeclampsia compared 
with control pregnancies, such as placental ERAP1 and 
2, increased in transcriptome profiling of preeclamptic 
tissues and higher AP-A (ANPEP) activity in preeclamp-
sia.47,59,60 This suggests an even higher shift towards Ang 
III and Ang IV, acting on placental LNPEP in pregnancies 
complicated by preeclampsia.
The importance of placental AGTR1 in early gesta-
tion depends on whether the fetal circulating RAS is 
established. We were not able to assess the availability 
of AGT in the fetal circulation in our study. While there 
are reports of Ang in term cord blood and thus the 
fetal circulation,61 there are no earlier measurements 
of plasma AGT in the fetal circulation yet. scRNA-seq 
of fetal hepatocytes in 15 to 21 post-conception week 
synthesizing AGT62 is the earliest available data, limiting 
comparison to our data from 7 post-conception week. 
However, this fact only adds to the importance of the 
maternal circulating RAS in this early pregnancy period 
before establishment of fetal RAS acting on placental 
AGTR1 in second trimester.62
Our results suggest a general shift of the maternal 
circulating RAS towards increased Ang IV levels with 
onset of pregnancy, which are met by the appearance 
of placental LNPEP at the maternal interface. The Ang 
IV-induced decrease of basal mitochondrial respira-
tion in trophoblasts may result in an attempt to rescue 
the placental metabolism by increasing leptin. Leptin in 
turn downregulates LNPEP expression, suggesting a 
negative feedback loop regulation of the Ang IV/leptin/
LNPEP axis. We found that LNPEP, involved in vasopres-
sin clearance and antigen cross-presentation, was down-
regulated in early and late-onset preeclampsia. More 
importantly, we could show that this effect was already 
observable in first trimester placentae from women that 
had a higher risk for developing preeclampsia based on 
a high uterine artery resistance index.
PERSPECTIVES
The study suggests for the first time the mechanisms 
by which hypertensive disorders in pregnancy may be 
connected to altered leptin and cellular metabolism. Fur-
thermore, our results indicate a new pharmacological 
RAS target. Since LNPEP is shed and found in maternal 
plasma only in pregnancy, it could serve as a novel tar-
get. In contrast to ARBs and ACE inhibitor, it may poten-
tially be nonteratogenic and serve as a more selective 
approach. Using LNPEP as pharmaceutical target may 
lower detrimental effects such as decreased mitochon-
drial respiration or increased maternal leptin levels that 
finally seem to contribute to the multifactorial disease in 
pregnancy, preeclampsia.
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